Skip to content
drillr.ai

VRTX

Vertex Pharmaceuticals Incorporated

NASDAQ · USHealthcareBiotechnology
$480.50-1.06%

Price as of Jul 20, 2026

VRTX news

Vertex Pharmaceuticals Incorporated news

A server-rendered, paginated timeline of the latest available company news.

  1. Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

    Vertex to Announce Second Quarter 2026 Financial Results on August 3rd Vertex Pharmaceuticals Incorporated (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.vrtx.com&esheet=54566424&newsitemid=20260707456160&lan=en-US&anchor=Vertex+Pharmaceuticals+Incorporated&index=1&md5=b87fffd5e6de7aa55e86b4049a85ab5c) (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call a

    Business Wire ·

  2. Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

    Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 Vertex Pharmaceuticals Incorporated (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vrtx.com%2F&esheet=54546984&newsitemid=20260603629281&lan=en-US&anchor=Vertex+Pharmaceuticals+Incorporated&index=1&md5=74ca17fa0f5f1aec0fa3fc3ff06330d4) (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, P

    Business Wire ·

  3. Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

    Vertex Announces CASGEVY(® )Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany -The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vrtx.com&esheet=54522277&newsitemid=20260424009095&lan=en-US&anchor=Vertex+Pharmaceuticals+Incorporated&index=1&md5=a

    Business Wire ·

  4. New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST

    Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / March 21, 2026 / New to The Street, one of the longest-running U.S. and international sponsored television brands, proudly announces the nationwide broadcast of Show #739, airing tonight at 6:30 PM EST on Bloomberg Television across the United States. This week's episode delivers a compelling lineup of innovativ

    ACCESSWIRE ·

  5. Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

    Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically significant and clinically meaningful 49.8% reduction in UPCR versus placebo (P<0.0001) – - For the first seconda

    Business Wire ·

  6. Vertex to Participate in Upcoming March Investor Conferences

    Vertex to Participate in Upcoming March Investor Conferences Vertex Pharmaceuticals Incorporated (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vrtx.com%2F&esheet=54439523&newsitemid=20260305227284&lan=en-US&anchor=Vertex+Pharmaceuticals+Incorporated&index=1&md5=7ede67e3e67aa13b3f3aae1bf8636682) (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. * Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief

    Business Wire ·

  7. Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

    Vertex to Present New Data on JOURNAVX(®) That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures -Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting- Vertex Pharmaceuticals Incorporated (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vrtx.com%2F&esheet=54438939&newsitemid=20260305

    Business Wire ·